Form 4: Biostem Technologies Director Reports Stock Transaction
Insider Transaction (Form 4)
Kenneth Howard Warrington Jr, a Director of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 1,694 Common Stock on September 15, 2026; holds 33,928 after (Direct).
- Option exercise/conversion: disposed of 1,694 Restricted Stock Units on September 15, 2026; holds 6,773 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kenneth Howard Warrington Jr — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 1,694 | — | — | 33,928 |
| 2026-09-15 | Option exercise/conversion | Restricted Stock Units | 1,694 | — | — | 6,773 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (1,694 shares) |
| 2026-09-15 | Option exercise/conversion (1,694 shares) |
Keywords
insider transaction, Form 4, BSEM, BioStem Technologies, Inc., neutral, Kenneth Howard Warrington Jr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.